NewStem, introduces a novel technology for predicting resistance to chemotherapy treatments. The Company is developing a diagnostic kit based on the pioneering research of Professor Nissim Benvenisty, the Azrieli Center for Stem Cells and Genetic Research, the Hebrew University of Jerusalem, in the field of human haploid pluripotent stem cells (HHPSCs). The novel technology will be presented at Yissum’s booth during the MIXiii Biomed 2017 Conference, to be held on May 23-25, in Tel Aviv, Israel.
Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University Ltd.’s nasal drug delivery technology.
Under the terms of the agreement, Yissum will grant Therapix an exclusive, worldwide, sub-licensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids.
The technology, developed by Professor Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective nasal absorption of tetrahydrocannabinol, or THC, the active pharmaceutical ingredient in the drugs developed by Therapix.
Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis
Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical programs and any required preclinical work necessary for regulatory approval.
Moebius Medical is an innovative clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. The company was founded in 2008 within the RAD Biomed Accelerator to develop products based on a patent-protected technology exclusively licensed from Yissum, the Hebrew University Technology Transfer Company, T3, the Technology Transfer arm of the Technion Institute, and by Hadasit, the Technology Transfer company of Hadassah Medical Center. To date, the company has been funded by RAD Biomed, PixVine Capital, a Singapore-based early stage VC fund, and Yissum, the technology transfer company of the Hebrew University of Jerusalem.
Revolutionary new technology gives cannabinoids unparalleled access to bloodstream.
Commercial launch by Ananada Scientific of HYGIA Nutrients Brand took place at the Marijuana Business Conference in Las Vegas.
Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today that Agrinnovation, an investment fund focused on agricultural inventions, has entered into an agreement for an investment in Cannabi-Tech Ltd., a medical cannabis company established in 2015, and based on research preformed in the laboratory of Prof. Oded Shoseyov from The Hebrew University's Robert H. Smith Faculty of Agriculture, Food and Environment.
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that RenewSense was selected to enter Brainnovation, Israel’s Brain Technologies accelerator.
RenewSenses, based on research from the lab of Professor Amir Amedi, from the Department of Medical Neurobiology at the Hebrew University of Jerusalem and the Edmond & Lily Safra Center for Brain Science, develops devices that can aid the blind and visually-disabled to navigate using other senses like sound and touch.
Yissum announced that it has signed a non-exclusive worldwide licensing agreement and a consulting agreement with Lightricks for the development and commercialization of an imaging technology that improves digital image processing. The technology, invented by Prof. Raanan Fattal from the School of Computer Science and Engineering at the Hebrew University of Jerusalem, is called “Edge Avoiding Wavelets” and it enables better and faster detail enhancement and preserves edges when sharpening digital images.
Non-invasive diagnostic test realizes the potential of circulating DNA for detection of multiple diseases
The novel technology was developed by Yinon Ben-Neriah, MD, PhD, Blumenthal Professor of Cancer Research, Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, with generous support by AMRF (The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation). Dr. Ben-Neriah and his team showed that inhibition of the clinically validated enzyme CKI-alpha induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation. This provides a novel approach to treat a wide range of cancers, in particular selective types of hematological malignancies.
Conference focusing on innovations in nanotechnology, sensors, coating materials, electronic and 3D printing, to take place on March 29 at Hebrew University Edmond J. Safra campus.
During 2015, Yissum founded a record number of eight companies based on inventions of researchers from the Hebrew University’s Center for Nanoscience and Nanotechnology.
JVP to Operate Jerusalem-based Startup Incubator for 8 Years in Partnership with Motorola Solutions, Reliance Industries and Yissum, the Research Development Company of the Hebrew University of Jerusalem
Neteera Technologies Raises 2 Million US Dollars.
Novel technology, based on electromagnetic properties of human sweat ducts, enables biometric identification along with monitoring of stress, fatigue, pain, alcohol influence, drug abuse detection, and medical diagnostics
Melodea develops environmentally-friendly, nano-crystalline cellulose based products from side streams of the paper industry
Capital to be used for completion of on-going Phase 2b study of ladostigil, for treatment of mild cognitive impairment, and preparations for pivotal Phase 3 trial
The first projects to be funded by Agrinnovation include protective coating for extension of shelf-life of fruits and vegetables, controlled release of drugs for farm animals, and invention for protection of plants via electronic means.
Results show positive trends in primary end point of delaying or preventing onset of Alzheimer’s diseaseFinal results expected in Q3 2016, following 3 years of treatment
The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs
Qlight Nanotech’s staff will remain at the Company’s site at the Hebrew University of Jerusalem, and will function as the research base for Merck for quantum-materials for the display and lighting industry
Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and TASE: ICL), a global manufacturer of products based on specialty minerals that fulfill essential needs of the world’s growing population in the agriculture, processed food and engineered materials markets.
The expanded collaboration includes a research agreement involving work in the field of materials and 3D printing of Prof. Shlomo Magdassi, the Casali Institute of Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University, as well as a research and license agreement for an invention in the field of solar energy by Dr. Lioz Etgar from the Institute of Chemistry at the Hebrew University.
Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. The drug was produced based on an invention by Prof. Simon Benita of the Hebrew University's Instuitute for Drug Research.